Biohaven presents new data with bhv-7000 once-daily extended-release formulation demonstrating excellent safety profile and nonclinical data updates at american epilepsy society 2024 annual meeting

Reported expanded safety results from bhv-7000 phase 1 multiple ascending dose studies, including the once-daily extended-release formulation being evaluated in ongoing phase 2 and 3 clinical studies , demonstrating excellent tolerability at all doses evaluated without central nervous system (cns) adverse effects typically associated with other anti-seizure medications (asms), such as somnolence and cognitive/mood disturbances. qualitative assessment of online social media platforms and forums provided a unique perspective of the unmet needs that people with epilepsy are vocalizing outside of the clinical setting, including the negative impact that asm associated adverse events have on their quality of life.
BHVN Ratings Summary
BHVN Quant Ranking